Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

MARBOFLOXACIN CRS (10 MG)

MARBOFLOXACIN CRS (10 MG)

115550-35-1

DISCOVER
Marbofloxacin for peak identification CRS, 20mg

Marbofloxacin for peak identification CRS, 20mg

115550-35-1

DISCOVER
MOLSIDOMINE CRS (5 MG)

MOLSIDOMINE CRS (5 MG)

25717-80-0

DISCOVER
MOLSIDOMINE IMPURITY B CRS (10 MG)

MOLSIDOMINE IMPURITY B CRS (10 MG)

59-89-2

DISCOVER
MOLSIDOMINE IMPURITY D CRS (10 MG)

MOLSIDOMINE IMPURITY D CRS (10 MG)

4394-85-8

DISCOVER
NIFLUMIC ACID CRS (10 MG)

NIFLUMIC ACID CRS (10 MG)

4394-00-7

DISCOVER
NIFLUMIC ACID IMPURITY A CRS (20 MG)

NIFLUMIC ACID IMPURITY A CRS (20 MG)

2942-59-8

DISCOVER
NIFLUMIC ACID IMPURITY B CRS (10 MG)

NIFLUMIC ACID IMPURITY B CRS (10 MG)

NA

DISCOVER
NIFLUMIC ACID IMPURITY E CRS (15 MG)

NIFLUMIC ACID IMPURITY E CRS (15 MG)

NA

DISCOVER
SERTRALINE HYDROCHLORIDE CRS (200 MG)

SERTRALINE HYDROCHLORIDE CRS (200 MG)

79559-97-0

DISCOVER
NILUTAMIDE CRS (110 MG)

NILUTAMIDE CRS (110 MG)

63612-50-0

DISCOVER
MORPHINE FOR SYSTEM SUITABILITY CRS - * NARC (MORPHINE HYDRO

MORPHINE FOR SYSTEM SUITABILITY CRS - * NARC (MORPHINE HYDRO

6211-15-0

DISCOVER